XM does not provide services to residents of the United States of America.
U
U

UCB

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Covivio, Mercedes-Benz Group, Persimmon

EUROPE RESEARCH ROUNDUP-Covivio, Mercedes-Benz Group, Persimmon Dec 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Covivio, Mercedes-Benz Group and Persimmon on Tuesday. HIGHLIGHTS * BMW BMWG.DE : UBS raises to buy from neutral * Covivio SA CVO.PA : Morgan Stanley cuts to underweight from equal weight * Hypoport SE HYQGn.DE : Exane BNP Paribas cuts to neutral from outperform * Mercedes-Benz Group AG MBGN.DE : Barclays cuts to un
B
B
B
B
C
C
E
H
H
L
P
P
R
R
R
S
U
V
T

UCB Receives U.S. FDA Approval For Bimzelx® (Bimekizumab-Bkzx)

BRIEF-UCB Receives U.S. FDA Approval For Bimzelx® (Bimekizumab-Bkzx) Nov 20 (Reuters) - Ucb SA UCB.BR : UCB RECEIVES U.S. FDA APPROVAL FOR BIMZELX® (BIMEKIZUMAB-BKZX) AS THE FIRST IL-17A AND IL-17F INHIBITOR FOR ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA Source text: ID:nPn9zTJhra Further company coverage: UCB.BR
U

UCB Receives U.S. FDA Approval For Bimzelx

BRIEF-UCB Receives U.S. FDA Approval For Bimzelx Nov 20 (Reuters) - Ucb SA UCB.BR : RECEIVES U.S. FDA APPROVAL FOR BIMZELX(BIMEKIZUMAB-BKZX) AS FIRST IL-17A AND IL-17F INHIBITOR FOR ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA APPROVAL IS SUPPORTED BY DATA FROM TWO PHASE 3 STUDIES, BE HEARD I AND BE HEARD II Source text: ID:nNDL295pXp Fu
U

UCB Presents Dapirolizumab Pegol Phase 3 Data

BRIEF-UCB Presents Dapirolizumab Pegol Phase 3 Data Nov 19 (Reuters) - Ucb SA UCB.BR : DAPIROLIZUMAB PEGOL PHASE 3 DATA SHOWS SIGNIFICANT REDUCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY DAPIROLIZUMAB PEGOL (DZP) MET ITS PRIMARY ENDPOINT Source text: ID:nGNX9FDwjP Further company coverage: UCB.BR (Gdansk Newsroom)
U

European pharma stocks slip after Trump taps RFK Jr to lead top US health agency

BUZZ-European pharma stocks slip after Trump taps RFK Jr to lead top US health agency ** Share in healthcare companies drop the most in Europe, hurt by the news that Donald Trump has selected Robert F. Kennedy Jr. , who has previously spread misinformation on vaccines, to lead the country's top health agency ** STOXX 600 Healthcare index .SXDP at -2.09% is the biggest faller among the pan-European indices ** At 1113.76 points, the sub-index is at its lowest in 7 months and is heading for its big
A
G
R
S
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.